Purpose: To optimize the acquisition parameters of single-voxel and of spectroscopic imaging
sequences for 1H-MRS of the prostate at 3.0 T in order to test the feasibility of highfield MRS of
the prostate without use of endorectal coils.
Methods: Single-voxel 1H-MRS (SVS) and 2D spectroscopic imaging (2D-SI) of the prostate gland were performed
with PRESS localization and water suppression by Gaussian excitation prepulses on
a clinical 3.0 T whole-body MR system (Intera Achieva 3.0 T, Philips Medical Systems).
A 6-element phase-array SENSE surface coil was used for MRI and MRS of the pelvis.
Measurements in a citrate phantom preceded the in-vivo study to optimize TE at 3.0
T for in-phase detection of the strongly coupled, non-equivalent citrate CH2 protons at δ=2.6 ppm. Applying a TR/TE of 1800/132 ms, 38 patients (mean age 66±7
y) with clinical suspicion (increased PSA values) of prostate cancer were investigated
before biopsy, and choline/citrate metabolite ratios as well as water T2 values (from
unsuppressed T2 relaxometry) were determined in comparison to the results from 10
healthy volunteers. While SVS with volume sizes of 5–8ml was acquired with 160 signal
averages, 2D-SI was performed with a 162 matrix over a FOV of 16cm and with a slice thickness of 1.5cm (voxel size 1.5ml).
Postprocessing was done by time-domain analysis using the MRUI software package.
Results: At 3.0 T, the citrate signal (Cit) revealed a quadruplet structure with 8Hz spacing
between the inner components and 16Hz distance (=J) to the outer lines, and with optimum
in-phase detection at a TE of 132 ms. As the in-vivo line widths of the methyl signals
of creatine (Cr), polyamines, and choline (Cho) sometimes prevented separate quantification
of all individual components, the total intensity t(ChoCr) of the peaks at 3.0–3.2
ppm and the ratio t(ChoCr)/Cit were also calculated in the patients and the controls.
This ratio was significantly higher in 12 patients with histologically confirmed prostate
cancer compared to healthy controls (0.85±0.27 vs. 0.67±0.07, p<0.05). Cho/Cit was
also increased in the cases with proven malignancy (0.45±0.29 vs. 0.26±0.06). However,
this was not significant due to the large variation within the tumor group. In 14
patients with benign prostate disease, the mean values for the metabolite ratios (t(ChoCr)/Cit=0.66±0.20
and Cho/Cit=0.30±0.11) well matched those of the controls. Using a cut-off value of
0.75 for t(ChoCr)/Cit, 8/12 cases of prostate cancer and 12/14 benign cases were diagnosed
correctly by MRS at 3.0 T (67% sensitivity, 86% specificity). Water T2 of prostate
tissue obtained from a bi-exponential fit was significantly prolonged in cases of
malignancy (mean value 62±7 ms vs. 55±5 ms in controls, p<0.05). Although a similar
T2 prolongation was observed in prostate hyperplasia, discrimination from malignant
disease was possible due to higher percentage of the free water (long-T2) component
in benign cases (19±9% vs. 10±6%, p<0.01).
Conclusion: In spite of the reduced rf penetration in body applications at 3.0 T, the signal gain
at higher field strengths allows 1H-MRS of the prostate with sufficient SNR using phase-array surface coils. The preliminary
results of our study indicate, that prostate MRS at 3.0 T without application of endorectal
coils is feasible and yields reliable diagnostic findings. Especially in cases with
reduced or missing MRI delineation of the peripheral zone, MRS may provide additional
information. Further improvement in the detection of small lesions and discrete infiltration,
however, demands 2D- or 3D-SI acquisition with voxel sizes <1ml, which may require
signal averaging and correspondingly longer measurement duration.
